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Recovery after ischemic stroke is slow and highly variable. Activated ROCK (Rho-associated coiled-coil kinase) 
pathway hampers recovery of impaired neurons. Though inhibiting ROCK pathway has shown therapeutic effects in vitro, 
the selectivity of most of the ROCK inhibitors is still not investigated. Present study aims to investigate the binding affinity 
in silico of nine widely used ROCK inhibitors with brainspecific ROCK2 isoform. Three-dimensional structures of ROCK2 and 
eight drugs were taken from Protein Data Bank and PubChem Chemical Compound Database, respectively, whereas, 
FSD-C10 structure was generated based on Xin et al., 2015. In docking, ROCK2 was set to be rigid and drugs were free to 
rotate. All simulations were carried out using AutoDock 4.2. This study demonstrated strong complexation between all 
ligands and ROCK2. All ROCK inhibitors, except FSD-C10, were able to bind to ROCK2 more strongly [Binding constant 
(Ka) between 2.6 – 36.7 × 10
5 M−1] than fasudil (Ka = 2.5 × 105 M−1). SLx-2119 (KD-025) had the highest binding constant
(Ka = 36.7 × 10
5 M−1) thus succeeding as a better ROCK2 specific inhibitor. Selectivity of ROCK inhibitors (in silico)
towards ROCK2 can be an indicative measure to estimate therapeutic benefits or adverse effects prior to in vitro study.  
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Stroke is the second most common cause for mortality 
among diseases of cardiovascular origin and has 
varying incidence, case-fatality, and mortality in 
different countries
1,2
. Years lived with disability is 
high among stroke patients with high morbidity even 
in developed countries
3
. Current managements aim to 
limit brain injury by immediate medical intervention 
and post-stroke rehabilitation measures to enhance 
clinical recovery
4,5
. Rehabilitation training alone 
is a major poststroke treatment strategy
6
. Hence 
therapeutic intervention that can complement the on-
going rehabilitative measures can hasten recovery and 
subsequently improve the quality of life. The injured 
axons of the central nervous system (CNS), as seen in 
stroke, have poor regenerative capacity due to a 
spurt of axonal growth inhibitors in the surrounding 
neuro-astroglial environment
7
. Activated ROCK 
(Rho-associated coiled-coil containing protein 
kinase/Rho-kinase) pathway in the injured neuronal 




The ROCKs are serine/threonine kinases and are 
major downstream targets of GTPase, RhoA. GTP-
bound RhoA activates ROCKs to phosphorylate a 
variety of substrates viz. myosin light chain 
neurofilament protein, myristylated alanine-rich 
C-kinase etc
10
. The ROCK2 isoform is specifically
expressed in the CNS and heart
11,12
. Anomalous
behaviour of ROCK in ischemic stroke and
breakdown of blood brain barrier is well established
in the literature. For example, high ROCK activity has
been reported within 48 h of acute ischemic stroke in
humans
13
 and it’s high expression (>2 folds) in the
ischemic region was reported in a mouse model of
middle cerebral artery occlusion
14
. Elevated levels of
phosphorylated myosin in ischemic brain wall
15
 and
reduced expression of endothelial nitric oxide
synthase in endothelial cells
16
 are all resultants of high
ROCK expression. Recently, expression of ROCK-2
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major role in proinflammatory cell adhesion molecule 
expression
17,18
. Hence, all these findings speculate the 
crucial role of ROCK-2 isoform in ischemic stroke 
and provide a vital therapeutic target. Several ROCK 
inhibitors, for example, fasudil and its derivatives 
have been investigated in vitro to investigate their role 
in neuronal regeneration.  
Many ROCK inhibitors (Rho kinase inhibitors) have 







 etc. In 
glaucoma, ROCK inhibitors such as K-115 and SNJ-
1656 lowered intra-ocular pressure
22,23
. It is important to 
note that most of the ROCK inhibitors are not target 
specific in their action and may bind to ROCK2 or other 
similar kinases. This non-specificity leads to several 
kinds of adverse effects like hypotension, intracranial 
haemorrhage, and abnormal hepatic and renal function, 
conjunctival hyperaemia, sporadic punctate sub-
conjunctival haemorrhage. Therefore, identifying the 
target specificity of drug molecules is a fundamental 
step to determine their usefulness.  
The present study aims to find out the binding 
affinity of selected inhibitors with ROCK2, the highly 
expressed ROCK isoform in CNS. We selected 
pharmacological ROCK inhibitors from a range  
of non-selective (fasudil), analogues of fasudil 
(hydroxy-fasudil and dimethyl-fasudil), and selective 
(SLx-2119) ROCK2 inhibitors to demonstrate their 
binding affinity using molecular docking simulations.  
 
Materials and Methods 
 
Sequence retrieval and protein two/three-dimensional 
structure 
The amino acid sequence of ROCK2 protein (ID: 
O75116; 1388 amino acids) of Homo sapiens was 
retrieved from the UniProt protein database (http:// 
www.uniprot.org). The sequence was used for the 
prediction of the secondary structure of the protein by 
using the online tool SAS-sequence annotated by 
structure (http://www.ebi.ac.uk/thornton-srv/databases/ 
sas/). The three-dimensional X-ray structure with 2.93 
Å resolution of ROCK2 protein (PDB ID: 4WOT) 
was downloaded from the structure database protein 
data bank (PDB) (www.rcsb.org/) which was further 
refined and energy minimized using Swiss-PDB 
Viewer (https://spdbv.vital-it.ch/). At last, the protein 
structure was validated using the RAMPAGE web-
tool (mordred.bioc.cam.ac.uk/~rapper/rampage.php).  
 
Ligand preparation 
The three-dimensional structures of therapeutic 
molecules (ligands) namely, dimethyl fasudil, fasudil,  
FSD-C10, K-115, SNJ-1656, Y-27632, hydroxy  
fasudil, SAR407899, SLx-2119 were generated by 
Marvinsketch (https://www.chemaxon.com/products/ 
marvin/marvinsketch/) and converted into the PDB 
format. It differentiates between drug like and non-
drug like molecules by predicting their possibilities of 
success or failure on interacting with the target 
protein. Our study evaluated the characteristics based 
on five parameters namely: mass of the ligand (less 
than 500 daltons), hydrogen bond donor (≤5), 
hydrogen bond acceptor (≤10), Log P (Octanol-water 
partition coefficient ≤5), and molar refractivity 
ranging between 40-130
24
. Complying with two or 
more rules reflects success in achieving major drug-
target protein interaction.  
 
Molecular docking 
A rigid docking methodology present in the 
AutoDock 4.2 software was followed while docking 
the filtered compounds against the ROCK2 (PDB ID: 
4WOT) target protein. The Autodock consist of two 
main programs, (1) autogrid, pre-calculates these 
grids, and (2) it performs the docking of the ligand to 
a set of grids describing the target protein. In addition 
to using them for docking, the atomic affinity grids 
can be visualized. A graphical user interface called 
auto dock tools (ADT) was utilized to generate grids, 
calculate dock score, and evaluate the conformers. All 
ligands under study (Suppl. Fig. 1) were docked to the 
model of the ROCK2 protein, using the Lamarckian 
genetic algorithm (LGA)
25
. The active site in the 3D 
structure was not defined and the blind docking 
procedure for the interaction study was performed in 
the study. Before performing the docking, the receptor 
was prepared using the MGL tool package. The grid 
size for the receptor for docking was given as 126 Å, 
126 Å, and 126 Å on X, Y & Z coordinates 
respectively, which makes sure that the search space 
covers the whole protein as a binding site and large 
enough for the ligand to rotate and find appropriate 
binding conformation. In addition to returning the 
docked structure, AutoDock also calculates free 
binding energy for each ligand-receptor configuration. 
The best ligand-receptor structure from the docked 




The toxicity profile of the selected nine (ligands) 
was analysed based on the Lipinski rule  
of five. The QSAR (quantitative structure-activity 
relationship) analysis showed that every ligand 




complied with all rules for druglikeness (Table 1) 
and therefore could be processed further for docking 
studies. 
The protein-ligand interaction between the ROCK2 
and ligands was assessed using AutoDock 4.2 
software. High binding or association constant (Ka) 
and high negative free energy (-ΔG) resulting from 
non-covalent interaction between respective ligand 
and ROCK2 demonstrate the drug’s potential in 
inhibiting the enzyme activity. The docked views of 
drug-enzyme interactions are shown in (Fig. 1) while 
(Table 2) depicts the association constants (Ka) and 
free energies (ΔG).  
Docking study showed that all nine ligands bind to 
ROCK2 and could be possible inhibitors of ROCK2 at a 
different strengths. The SLx-2119 and ROCK2 complex 
demonstrated the highest binding constant and  
lowest ΔG values than other ligand-ROCK2 complexes 
(Table 2). The polar contacts between ROCK2 and the 
respective ligands are shown in (Table 3). We observed 
a maximum number of polar contacts for SLx-2119 and 
hydroxy fasudil (five each) while SNJ-1656 having four 
polar contacts with target ROCK2 showing their 
different degree of interactions. 
 
Discussion 
The present study demonstrates the differential 
binding efficiency of nine potential Rho kinase 
inhibitors with ROCK2 enzyme in silico. The SLx-
2119 showed the highest binding efficiency among all 
ligands studied and FSD-C10 possessed the weakest 
interaction with ROCK2 (Table 2). ROCK2, which is 
highly expressed in brain endothelial cells, is one of 
the lead molecules responsible for poor regeneration 
of neurons
26
. Inhibition of ROCK2 is a promising way 
which can promote axonal regeneration and 
functional recovery. Several ROCK inhibitors have 
been proven beneficial by increasing neurite 
regeneration, neuroprotective, and altering inflammation. 





 have been shown high specificity for 
ROCK2 isoform in vitro. However, their interaction 
with ROCK2 is still unknown. Our in silico docking 
analysis shows that all the nine inhibitors can  
bind and inhibit ROCK2 but with variable selectivity 
(Fig. 1 & Table 2). The utility of the selected 
inhibitors is currently limited to preclinical studies 
except for fasudil, which is approved in Japan and 
China for human use
29,30
. 
Fasudil, in a double-blinded study, has been shown to 
improve clinical outcomes in acute ischemic stroke with 
no significant adverse effects
29
 and also demonstrated a 
vasodilator effect in several studies. Analogues of 
fasudil, hydroxy fasudil (active metabolite of fasudil), 
and dimethyl fasudil have also shown similar ROCK 
inhibition properties in reducing cerebral infarction and 
inflammation
31
 and restoring neurite regeneration  
in vitro
32
, respectively. The FSD-C10, another fasudil 
analogue, too have shown similar effects on neuronal 
regeneration but with significantly much lower toxicity 
than fasudil
33
. Considering fasudil as a starting molecule 
from which several ROCK inhibitors have been 
developed; almost all its derivatives demonstrated  
higher binding affinity with ROCK2 in our in  
silico study (Table 2 & Fig. 1). Among the four  
drugs (fasudil, hydroxy fasudil, dimethyl fasudil  
and FSD-C10), hydroxy  fasudil  surpassed the binding  
Table 1 — The QSAR description of ligands under study 
S. No. Ligand Mass Hydrogen Bond Donor Hydrogen Bond Acceptor Log P Molar Refractivity 
1 Dimethyl Fasudil 320 2 4 1.97 86.15 
2 Fasudil 292 2 4 1.27 76.82 
3 FSD-C10 290 0 4 3.88 78.99 
4 K-115 308 4 5 −0.12 75.57 
5 SNJ-1656 281 5 3 2.12 81.79 
6 Y-27632 248 4 3 1.46 70.66 
7 Hydroxy Fasudil 308 3 5 0.44 78.02 
8 SAR407899 245 3 3 0.51 68.25 
9 SLx-2119  452 3 7 4.63 132.46 
Table 2 — Docking analysis of ligands-ROCK2 association 
Drug (Ligand) Association constant 
(Ka × 105 M−1) 
Free energy (∆G) 
(Kcal/mol) 
SLx-2119 (KD-025) 36.7 −9.07 
SNJ-1656 23 −8.79 
Hydroxy fasudil 13.7 −8.48 
Dimethyl fasudil 9.2 −8.24 
K-115 7.9 −8.15 
SAR407899 4.7 −7.83 
Y27632 2.6 −7.47 
Fasudil  2.5 −7.46 
FSD-C10 2.2 −7.39 







Fig. 1 — Molecular docking poses of various ROCK inhibitors (ligands) with ROCK2 
 
Table 3 — Polar contacts between ROCK2 and various ligands 
Ligand Polar Contacts Distance (Å) 
Receptor Residue Ligand Atoms 
Y27632 116 O GLU A 196 H UNK 2.1 
76 NZ LYS A 195 O UNK 2.6 
155 O ALA A 195 O UNK 2.8 
Fasudil 72 O GLU A 142 H UNK 2.1 
111 O ALA A 137 O UNK 2.7 
FSD-C10 43 N VAL D 12 O UNK 2.0 
33 O LEU D 12 O UNK 3.1 
43 N VAL D 13 O UNK 2.7 
44 H GLU D 13 O UNK 1.9 
Dimethyl Fasudil 64 N VAL D 140 O UNK 2.9 
71 N GLU D 140 O UNK 3.2 
103 O TYR D 144 N UNK 3.4 
K-115 19 OE2 GLU B 172 H UNK 2.2 
83 N VAL D 164 O UNK 2.8 
90 N GLU D 164 O UNK 3.0 
SNJ-1656 121 OD1 ASP A 195 H UNK 1.7 
114 OD2 ASP A 194 H UNK 2.1 
15 OD1 ASP A 190 N UNK 3.1 
101 O GLN A 193 O UNK 3.4 
Hydroxy Fasudil 231 O ALA A 11 O UNK 2.9 
  (Contd.) 




Table 3 — Polar contacts between ROCK2 and various ligands 
Ligand Polar Contacts Distance (Å) 
 121 HZ2 LYS A 11 O UNK 2.0 
232 OD2 ASP A 11 O UNK 3.2 
232 OD2 ASP A 12 H UNK 2.2 
176 OD2 ASP A 21 H UNK 1.9 
SAR407899 218 OD2 ASP A 12 H UNK 2.7 
218 H ASP A 11 O UNK 1.7 
291 OD1 ASP A 21 H UNK 1.8 
SLx-2119 
(KD-025) 
98 O ILE A 1 N UNK 3.4 
349 O ARG A 34 H UNK 1.8 
121 H LYS A 20 O UNK 2.0 
232 OD2 ASP A 20 O UNK 3.4 
231 O ALA A 20 O UNK 3.4 
 





ΔG = −8.48 Kcal/mol) while FSD-C10 showed least 





ΔG = −7.39 Kcal/mol), almost equal to fasudil  




, ΔG = −7.46 Kcal/mol). High Ka 
and high negative ΔG depict strong binding and hence 
more potent inhibition of the target enzyme. These 
results demonstrate hydroxy fasudil could be a more 
potent inhibitor of ROCK2 than fasudil, dimethyl 
fasudil, and FSD-C10.  
The ROCK inhibitors, SAR407899 and SLx-2119 
(KD-025) have also shown the potential to lower 
blood pressure and relieve vascular occlusion in focal 
cerebral ischemic cases
28,34
. The SAR407899 is a 
potent vasodilator and reduces blood pressure in 
experimental animals
34,35
 and also have been reported 
to reduce phosphorylation of MYPT (Myosin-
associated phosphatase) in vitro and ex vivo
34
. The 
SLx-2119 is more specific to ROCK2 and has been 
shown to enhance cerebral perfusion in local cerebral 
ischemic regions of the mouse brain and protects  
from rt-PA (recombinant plasminogen activator) 
thrombolysis induced cerebrovascular damage
26,28
. 
Our in silico binding analysis found that SLx-2119 





ΔG= −9.07 Kcal/mol) (Table 2 & Fig. 1) with ROCK2 
as compared to eight other drugs tested and hence 
possess high potency to inhibit ROCK2 isoform. 
The optic nerve is an integral part of the CNS has 
shown distinctive regeneration potential with the 
instillation of ROCK inhibitors
23,36
. In ocular diseases, 
inhibition of Rho kinase/ROCK pathway has been 
shown to reduce intra-ocular pressure and promote 
optic nerve regeneration
32
. In our study, we included 
ROCK inhibitors, K-115 (ripasudil; a fasudil 
derivative), SNJ-1656, and Y27632, which has been 
explored earlier in an ocular disorders like 
glaucoma
23,24,37
 but their therapeutic benefits in 
ischemic stroke is not yet explored in human subjects. 
The K-115 has been shown to enhance the survival of 
retinal ganglion cells after optic nerve crush and 
reduced Nox1 expression
23
. Recently, the clinical trial 
of K-115 has led to avoid glaucoma surgery in 35 
patients by lowering of intraocular pressure with well 
tolerability up to three months
38
. Similarly, Y27632 
induced optic nerve regeneration beyond the crush 
site in a dose dependent manner in adult cats
39
. The 
SNJ-1656, an ocular ROCK inhibitor that reduced the 
intraocular pressure with minimal side effects has 
been shown to enhance axonal regeneration in rat 
retinal ganglion cells
27
. In our molecular docking 
study, we found that SNJ-1656 also establishes 
thermodynamically favourable interactions with 





, ΔG= −8.79) (Table 2 & Fig. 1). Further  
in vitro studies are needed to prove their therapeutic 
potential in stroke. 
An earlier clinical trials with ROCK inhibitor 
fasudil did not establish any significant adverse 
effects
29
. Moreover, ROCK inhibitors, viz. fasudil 





, amyotrophic lateral 
sclerosis
42
 and have shown beneficial effects. 
Similarly, preclinical studies in mouse stroke models 
have shown SLx-2119 to be relatively safe with no 
substantial hypotensive events
28
. However, blood 
pressure fluctuation, systemic vasodilation, hypotension 
and hepatotoxicity are few adverse effects that should 
be specially gauged and monitored during a clinical 





identifying the selectivity of ROCK inhibitors is 
necessary to reduce toxicity. No ROCK inhibitors, 




other than fasudil (only in Japan and China)
29,30
 are 
approved for human use due to their adverse effects. 
Selectivity towards a particular ROCK isoform is the 
prime step towards the reduction of toxicity and 
subsequently, their delivery to target tissues/organs 
can further reduce adverse effects and raise their 
bioavailability. 
In our novel in silico molecular docking study, we 
observed all the nine ROCK inhibitors can potentially 
bind with ROCK2 which is highly expressed in the brain 
and during CNS injury. Our study also shows that SLx-
2119, SNJ-1656, and fasudil analogues, hydroxy fasudil, 
and dimethyl fasudil bind more strongly to ROCK2 and 
may be better ROCK inhibitors than fasudil itself.  
The high selectivity of SLx-2119 towards ROCK2 has 
already been shown
28,43
. Moreover, anti-glaucoma drug 
SNJ-1656 has shown higher potency as compared to 
fasudil in terms of ROCK2 interaction (Tables 2 & 3). 
We got very little binding of FSD-C10 with ROCK2 
which has shown more ROCK2 selective in vitro
33,44
. 
This requires more investigations in different types of 
conditions. Thus, from in silico perspective, this study 
highlights the interaction of widely studied nine ROCK 
inhibitors with ROCK2 which can facilitate early 
neuronal regeneration by impeding ROCK2 activity 
following stroke.  
 
Strength and limitation 
The in silico work is quick and does not require an 
animal or cell line model to evaluate the efficiency of 
any drug/ligand. Hence, such studies are cost-
effective, safe and time saving. In addition, docking 
studies are easy-to-use workflows of systems biology 
that utilizes every detail of the data (of drugs/ 
proteins/DNA) and obtain consensus predictions of 
small molecule activities and their off-target 
interactions
45
. However, further clinical studies are 
required to ascertain its efficacy, safety, and outcome 
in animal and human subjects so that they can further 
be used in clinics. 
 
Conclusion 
Following a stroke, the management currently 
emphasizes secondary prevention and rehabilitation 
measures. Molecular analysis reveals that certain 
cellular pathways impair the neural regeneration 
process. Rho kinase/ROCK pathway is one such 
molecular signalling mechanism. While numerous 
potent ROCK inhibitors are under trial, selectivity 
towards ROCK isoforms is always a challenging task. 
In this maiden in silico molecular docking study, we 
have assessed the strength of interaction of nine 
ROCK inhibitors against ROCK2. We found SLx-
2119 to possess the highest propensity to bind 
ROCK2 which is in concordance with its in vitro 
studies elsewhere in the neural tissue enhancing 
regenerative potential. The safety, efficacy, and 
pharmacokinetics of this drug in human subjects need 
to be further established. 
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